Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05080166

UPLYFT For Lymphoma Survivors

Led by Dana-Farber Cancer Institute · Updated on 2026-02-24

74

Participants Needed

1

Research Sites

237 weeks

Total Duration

On this page

Sponsors

D

Dana-Farber Cancer Institute

Lead Sponsor

A

American Society of Hematology

Collaborating Sponsor

AI-Summary

What this Trial Is About

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

CONDITIONS

Official Title

UPLYFT For Lymphoma Survivors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)
  • Age 218 years or older
  • Completed first-line treatment between 3 months and 24 months ago
  • Currently in complete remission after first-line treatment
  • Clinically significant fear of cancer recurrence (score 216 on the FCR Inventory-Severity Subscale)
  • Access to a computer for videoconferencing
  • Lymphoma clinicians with at least 1 year since oncology fellowship completion or mental health clinicians with at least 1 year since clinical training
  • Providing longitudinal clinical care for lymphoma patients or cancer patients (for clinicians)
Not Eligible

You will not qualify if you...

  • Age less than 18 years
  • Concurrent other malignancy
  • Uncontrolled or untreated psychotic disorders
  • Untreated bipolar or borderline personality disorder
  • Adults unable to consent
  • Individuals younger than 18 years (infants, children, teenagers)
  • Pregnant women
  • Prisoners

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Actively Recruiting

Loading map...

Research Team

O

Oreofe O Odejide, MD, MPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here